| 1. |
|
|
| 2. |
|
|
| 3. |
- Campbell, PJ, et al.
(author)
-
Pan-cancer analysis of whole genomes
- 2020
-
In: Nature. - : Springer Science and Business Media LLC. - 1476-4687 .- 0028-0836. ; 578:7793, s. 82-
-
Journal article (peer-reviewed)abstract
- Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Chung, SH, et al.
(author)
-
Risk factors for mortality in diabetic peritoneal dialysis patients
- 2010
-
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. - : Oxford University Press (OUP). - 1460-2385. ; 25:11, s. 3742-3748
-
Journal article (peer-reviewed)
|
|
| 7. |
|
|
| 8. |
- Koh, HS, et al.
(author)
-
The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia
- 2015
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 6, s. 6340-
-
Journal article (peer-reviewed)abstract
- Inflammation is closely related to the extent of damage following cerebral ischaemia, and the targeting of this inflammation has emerged as a promising therapeutic strategy. Here, we present that hypoxia-induced glial T-cell immunoglobulin and mucin domain protein (TIM)-3 can function as a modulator that links inflammation and subsequent brain damage after ischaemia. We find that TIM-3 is highly expressed in hypoxic brain regions of a mouse cerebral hypoxia-ischaemia (H/I) model. TIM-3 is distinctively upregulated in activated microglia and astrocytes, brain resident immune cells, in a hypoxia-inducible factor (HIF)-1-dependent manner. Notably, blockade of TIM-3 markedly reduces infarct size, neuronal cell death, oedema formation and neutrophil infiltration in H/I mice. Hypoxia-triggered neutrophil migration and infarction are also decreased in HIF-1α-deficient mice. Moreover, functional neurological deficits after H/I are significantly improved in both anti-TIM-3-treated mice and myeloid-specific HIF-1α-deficient mice. Further understanding of these insights could serve as the basis for broadening the therapeutic scope against hypoxia-associated brain diseases.
|
|
| 9. |
|
|
| 10. |
- Chung, SH, et al.
(author)
-
Impact of incremental risk factors on peritoneal dialysis patient survival: proposal of a simplified clinical mortality risk score
- 2009
-
In: Blood purification. - : S. Karger AG. - 1421-9735 .- 0253-5068. ; 27:2, s. 165-171
-
Journal article (peer-reviewed)abstract
- <i>Background/Aim:</i> Peritoneal dialysis (PD) patient survival is influenced by many factors and there is no consensus on the relative importance of these predictors, independently or combined. This study was designed to evaluate how these independent factors, alone or in various combinations, may influence PD patient survival. <i>Methods:</i> A peritoneal equilibration test, subjective global assessment (SGA), and comorbid diseases (CMD) were assessed. <i>Results:</i> On multivariate analysis, age (>60 years), CMD, malnutrition, and low RRF (≤2 ml/min) were independent predictors of mortality. Three-year patient survival was 100, 95, 75, 49, and 0%, and the risk ratio for mortality was 1.0, 6.6, 21.9, and 85.9 in patients with none, one, two, three, and four of these risk factors, respectively. <i>Conclusions:</i> The combination of independent predictors of mortality in PD patients leads to a markedly increasing risk for mortality. Evaluation of a single risk factor underestimates the true impact of risk factors.
|
|
